Pioneering the next generation of pulmonary medicine and microbiome science
Changes in microbial signatures of the lungs and airways are associated with worsening chronic respiratory disease and persistent inflammation. Alveolus Bio is focused on harnessing the therapeutic power of commensal bacteria strains and their byproducts for inhaled delivery straight to the target tissue: the lungs.
Alveolus Bio began in Dr. Vivek Lal’s Pulmonary Microbiome Lab and Dr. Amit Gaggar’s Program in Lung Protease and Matrix Biology at the University of Alabama at Birmingham (UAB).
The collaborating scientists published groundbreaking research on the neonatal lung microbiome, and became one of the first to conduct gain and loss of function studies on underlying mechanisms of neutrophilic inflammation and the extracellular matrix of the lung.
At the heart of Alveolus Bio is world class infrastructure and personnel to support preclinical drug development for various respiratory diseases.
Alveolus Bio serves as a platform for respiratory drug development from discovery to clinical trials.
Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD (2021)
Emerging evidence indicates that early life events can increase the risk for developing chronic obstructive pulmonary...
Early airway microbial metagenomic and metabolomic signatures are associated with development of severe bronchopulmonary dysplasia (2018)
The pathogenesis of bronchopulmonary dysplasia (BPD) is not well understood. We previously identified differences in...
Alterations of pulmonary microbiome have been recognized in multiple respiratory disorders. It is critically important...